Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin&#39;s lymphoma.

BRL-201 - BRL Medicine

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

Biao Zheng; YongXian Hu; Jiqin Zhang; Mingming Zhang; Wei Li; Wenjun Wu; Jiazhen Cui; Guoqing Wei; Bing Du; Mingyao Liu; He Huang

Apr 25, 2024